

Ulcerative Colitis

**A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)**

**Trial Status**  
Recruiting

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT06137183 2023-506655-19-00  
GA44839

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT06137183 2023-506655-19-00 GA44839**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---